We are facing a global brain disease crisis, but we are lacking targeted, effective medicines. Patients deserve better. Recent scientific and technological advancements have revolutionized precision medicines in oncology, and it’s time to develop precision medicines for brain diseases to change the status quo. Learn More.

Neumora has a broad pipeline of novel medicines for neuropsychiatric disorders and neurodegenerative disorders, each of which will be paired with a proprietary Precision Phenotype™ to ensure a targeted approach to development.

Neumora was founded to improve the lives of patients with brain diseases. A significant challenge is a lack of targeted, effective medicines. We founded Neumora to pioneer a new era in neuroscience by taking a fundamentally different approach to the way treatments for brain diseases are developed.

Neumora was founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our goal is to redefine...

2025年3月3日 · Neumora Therapeutics, Inc. KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026

2021年10月7日 · Having quietly put the startup together over the past 18 months, Thursday Arch unveiled Neumora Therapeutics—a biotech that starts life with $500 million, a collaboration with Amgen and a...

WATERTOWN, Mass., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA) a clinical-stage biopharmaceutical company with a therapeutics pipeline consisting of seven clinical and pre-clinical brain disease programs, today announced results from the Phase 3 KOASTAL-1 Study of navacaprant for the treatment of major depressive ...

2025年1月2日 · Neumora’s mission is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients living with brain diseases.

2025年3月4日 · Neumora Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for ...

2025年2月13日 · Neumora Therapeutics CEO Henry Gosebruch is leaving the brain drug developer in a reshuffling of its executive ranks that will involve board chair and company co-founder Paul Berns becoming chief executive. In addition, Chief Financial Officer Joshua Pinto will become president; Chief Strategy Officer Bill Aurora will serve as chief operating ...